Biomecite Diagnostics to Develop IBD Diagnosis Tool from UMB

Biomecite Diagnostics to Develop IBD Diagnosis Tool from UMB
The University of Maryland (UM) Ventures has established an agreement with Biomecite Diagnostics, LLM, giving the company the exclusive option for the rights to developing novel methods for diagnosing inflammatory bowel diseases (IBD) from the University of Maryland in Baltimore (UMB). The licensed technology was created by Florian Fricke and James White and is expected to improve detection of ulcerative colitis (UC) and Crohn's disease. The detection technology was developed while the two investigators were working at the University of Maryland School of Medicine's Institute for Genome Sciences (IGS). The technology works by exploring the distinct genomic variances in the bacteria or microbiome that are present in the gut in order to improve accuracy in diagnosing gastrointestinal conditions, such as ulcerative colitis and Crohn's, according to a press release from the company. "Biomecite Diagnostics is a particularly exciting UMB startup," stated the chief commercialization officer at UM Ventures, Phil Robilotto. "
Subscribe or to access all post and page content.